It is very uncertain whether anti‐TB therapy changes relapse compared with placebo (very low certainty).
It is very uncertain whether anti‐TB therapy changes adverse events compared with placebo (very low certainty).
It is very uncertain whether anti‐TB therapy changes withdrawals due to adverse events compared with placebo (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes cure compared with daily anti‐TB regimens (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes death from any cause compared with daily anti‐TB regimens (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes relapse compared with daily anti‐TB regimens (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes adherence to treatment compared with daily anti‐TB regimens (very low certainty).
It is very uncertain whether intermittent short‐course anti‐TB regimens changes treatment‐limiting adverse events compared with daily anti‐TB regimens (very low certainty).